Effect of low-dose amiodarone and magnesium combination on atrial fibrillation after coronary artery surgery
| Autor: | Cemal Levent Birincioglu, Kumral Ergun, Ozcan Ozeke, Mustafa Paç, Baran Budak, Ertan Demirtas, Kerim Cagli |
|---|---|
| Rok vydání: | 2006 |
| Předmět: |
Pulmonary and Respiratory Medicine
Relative risk reduction Male medicine.medical_specialty Turkey Amiodarone Coronary Artery Disease law.invention Coronary artery disease Electrocardiography Magnesium Sulfate Randomized controlled trial law Risk Factors Internal medicine Atrial Fibrillation medicine Humans Prospective Studies Coronary Artery Bypass Prospective cohort study Aged medicine.diagnostic_test Dose-Response Relationship Drug business.industry Incidence Atrial fibrillation Middle Aged medicine.disease Regimen Treatment Outcome Research Design Anesthesia Injections Intravenous Cardiology Surgery Drug Therapy Combination Female Cardiology and Cardiovascular Medicine business Anti-Arrhythmia Agents medicine.drug |
| Zdroj: | Journal of cardiac surgery. 21(5) |
| ISSN: | 0886-0440 |
| Popis: | Background To evaluate whether postoperative administration of intravenous low-dose amiodarone and magnesium sulfate (MgSO(4)) combination would reduce the incidence of atrial fibrillation following coronary artery bypass grafting (CABG) in normomagnesemic high-risk patients for postoperative atrial fibrillation (POAF). Methods A total of 136 patients undergoing elective CABG and had > or =3 risk factors for POAF were prospectively randomized to one of three groups, to receive a single dose of amiodarone (5 mg/kg) and MgSO(4) (1.5 g) (combination group, n = 44), or an equal dose of amiodarone (amiodarone group, n = 44) or equal volumes of saline (control group, n = 48) at early postoperative period. Continuous electrocardiographic (ECG) monitoring was performed for the first 48 hours and an ECG was recorded every 8 hours later. POAF longer than 30 minutes or for any length requiring treatment, and the drug-related side effects were recorded. Results The study population showed a homogeneous distribution regarding risk factors for POAF and there was no significant difference in patient characteristics, echocardiographic variables, or operative variables among three groups. POAF developed in 4 patients in combination group, in 16 patients in amiodarone group and in 16 patients in control group, representing a 24% relative risk reduction between the combination group and control group (p = 0.023). No statistically significant difference regarding incidence of POAF was observed between amiodarone and control groups. Conclusions Combined prophylactic therapy with amiodarone and MgSO(4) at the early postoperative period without a maintenance phase is an effective, simple, well-tolerated, and possibly cost-effective regimen to prevent POAF in normomagnesemic, high-risk patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|